Eloxx Pharmaceuticals (ELOX) Registration filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company focused on small molecule therapies that modulate the ribosome to promote readthrough of nonsense mutations (NMs), addressing genetic diseases with high unmet need.

• Lead candidate exaluren targets rare kidney diseases, notably Alport syndrome with NMs (NMAS), and is also being explored for autosomal dominant polycystic kidney disease (ADPKD) with NMs.

• ZKN-013, an oral ribosome modulating agent, is licensed to Almirall for rare skin diseases, with potential milestone and royalty payments.

• Pipeline includes preclinical and clinical programs for additional NM-driven diseases.

Financial performance and metrics

• Net loss for 2025 was $6.0 million; net loss for Q1 2026 was $3.8 million; accumulated deficit as of March 31, 2026 was $304.3 million.

• License and service revenue of $6.4 million in 2024 from Almirall; no product sales to date.

• Cash and cash equivalents as of March 31, 2026 were $6.4 million; working capital deficit of $7.6 million.

• Financing activities in 2025–2026 included $15 million from Coastlands Capital Partners and $2 million from Domicilium, with significant debt converted to equity.

Use of proceeds and capital allocation

• Proceeds will fund exaluren clinical development for NMAS through Phase 2b topline data and for nmADPKD through completion of Phase 2 trial.

• Remaining funds allocated to working capital and general corporate purposes.

• Company will have broad discretion over use of proceeds; actual allocation may vary based on clinical progress and operational needs.